A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

1,549

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Breast Neoplasms
Interventions
DRUG

exemestane

Exemestane 25 mg oral tablet once daily for a maximum of 3 years

Trial Locations (61)

1000

Pfizer Investigational Site, Brussels

1020

Pfizer Investigational Site, Brussels

1040

Pfizer Investigational Site, Brussels

1050

Pfizer Investigational Site, Brussels

1070

Pfizer Investigational Site, Brussels

1180

Pfizer Investigational Site, Brussels

1200

Pfizer Investigational Site, Brussels

1210

Pfizer Investigational Site, Brussels

1340

Pfizer Investigational Site, Ottignies

1420

Pfizer Investigational Site, Braine-l'Alleud

1500

Pfizer Investigational Site, Halle

2020

Pfizer Investigational Site, Antwerp

2170

Pfizer Investigational Site, Merksem

2300

Pfizer Investigational Site, Turnhout

2500

Pfizer Investigational Site, Lier

2570

Pfizer Investigational Site, Duffel

2610

Pfizer Investigational Site, Wilrijk

2650

Pfizer Investigational Site, Edegem

2800

Pfizer Investigational Site, Mechelen

2820

Pfizer Investigational Site, Bonheiden

2930

Pfizer Investigational Site, Brasschaat

3000

Pfizer Investigational Site, Leuven

3500

Pfizer Investigational Site, Hasselt

3600

Pfizer Investigational Site, Genk

3700

Pfizer Investigational Site, Tongeren

4000

Pfizer Investigational Site, Liège

Pfizer Investigational Site, Rocourt

4032

Pfizer Investigational Site, Chênée

4040

Pfizer Investigational Site, Herstal

4100

Pfizer Investigational Site, Seraing

4500

Pfizer Investigational Site, Huy

4700

Pfizer Investigational Site, Eupen

4800

Pfizer Investigational Site, Verviers

5000

Pfizer Investigational Site, Namur

5004

Pfizer Investigational Site, Bouge

5530

Pfizer Investigational Site, Yvoir

6000

Pfizer Investigational Site, Charleroi

6041

Pfizer Investigational Site, Gosselies

6060

Pfizer Investigational Site, Gilly (Charleroi)

6110

Pfizer Investigational Site, Montigny-le-Tilleul

6460

Pfizer Investigational Site, Chimay

6700

Pfizer Investigational Site, Arlon

6800

Pfizer Investigational Site, Libramont

7000

Pfizer Investigational Site, Mons

7060

Pfizer Investigational Site, Soignies

7100

Pfizer Investigational Site, La Louvière

7300

Pfizer Investigational Site, Boussu

7301

Pfizer Investigational Site, Hornu

7331

Pfizer Investigational Site, Baudour

7500

Pfizer Investigational Site, Tournai

7700

Pfizer Investigational Site, Mouscron

8000

Pfizer Investigational Site, Bruges

8500

Pfizer Investigational Site, Kortrijk

8790

Pfizer Investigational Site, Waregem

8800

Pfizer Investigational Site, Roeselare

8820

Pfizer Investigational Site, Torhout

9000

Pfizer Investigational Site, Ghent

9100

Pfizer Investigational Site, Sint-Niklaas

9200

Pfizer Investigational Site, Dendermonde

9300

Pfizer Investigational Site, Aalst

B-1040

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY